SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

RAGE GUY (RAGE) is a cryptocurrency inspired by the Rage Guy meme, one of the earliest and most recognizable characters from internet rage comics. The project captures the cultural legacy of early meme history and brings it onto the blockchain in tokenized form. It is designed as a community-driven digital asset that celebrates internet culture, nostalgia, and the role memes play in shaping online communities.

Rage Guy

$RAGE is trending as the community rallies around the meme coin, emphasizing community-driven growth and a return to OG meme culture within the crypto space. Discussions highlight the importance of organic growth, community engagement, and a rejection of reliance on traditional marketing tactics. The community expresses strong bullish sentiment, with many calling for others to join the movement.

Apple, Inc. engages in the design, manufacture, and sale of smartphones, personal computers, tablets, wearables and accessories, and other varieties of related services. It operates through the following geographical segments: Americas, Europe, Greater China, Japan, and Rest of Asia Pacific. The Americas segment includes North and South America. The Europe segment consists of European countries, as well as India, the Middle East, and Africa. The Greater China segment comprises China, Hong Kong, and Taiwan. The Rest of Asia Pacific segment includes Australia and Asian countries. Its products and services include iPhone, Mac, iPad, AirPods, Apple TV, Apple Watch, Beats products, AppleCare, iCloud, digital content stores, streaming, and licensing services. The company was founded by Steven Paul Jobs, Ronald Gerald Wayne, and Stephen G. Wozniak in April 1976 and is headquartered in Cupertino, CA.

Apple Inc

Apple is trending despite mixed sentiment following earnings, as the community debates whether positive guidance and a strong iPhone outlook outweigh concerns about declining sales in China. Bulls are hopeful for a continued rally, while bears point to the already high valuation and potential for a sell-off. Discussion also revolves around Apple's AI strategy relative to its tech peers.

Amazon.com, Inc. is a multinational technology company, which engages in the provision of online retail shopping services. It operates through the following segments: North America, International, and Amazon Web Services (AWS). The North America segment offers retail sale of consumer products, including from sellers, advertising, and subscriptions services through North America-focused online and physical stores. The International segment focuses on retail sale of consumer products, including from sellers, advertising, and subscription services through internationally-focused online stores. The AWS segment is composed of global sales of compute, storage, database, and other services for start-ups, enterprises, government agencies, and academic institutions. The company was founded by Jeffrey P. Bezos in July 1994 and is headquartered in Seattle, WA.

Amazon.com Inc.

Amazon.com Inc

Amazon is trending due to strong Q3 earnings, particularly driven by growth in AWS and advertising services, leading to a surge in market cap. The community is actively discussing potential price targets, with many analysts raising their outlook, while some debate whether the gains are sustainable. There is also discussion around the company's AI strategy and its impact on future growth.

Strategy, Inc. engages in the provision of enterprise analytics and mobility software. The firm designs, develops, markets, and sells software platforms through licensing arrangements and cloud-based subscriptions and related services. Its product packages include Hyper. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Vienna, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

Strategy ($MSTR) is trending amid discussions of a potential squeeze and upgrades to analyst price targets. Community members are actively debating the stock's correlation with Bitcoin's price movements and speculating on upcoming catalysts. Bullish sentiment seems to be increasing following earnings, though some remain skeptical of the company's business model.

Lumen Technologies, Inc. is an investment holding company, which engages in the provision of integrated communications to residential and business customers. It operates through the Business and Mass Markets segments. The Business segment provides products and services under four sales channels to enterprise and commercial customers. The Mass Markets segment focuses on consumer and small business customers. The company was founded in 1930 and is headquartered in Monroe, LA.

Lumen Technologies Inc

Lumen Technologies is trending as investors discuss its recent earnings beat and progress in its AI and enterprise growth strategy. Community members are focused on the company's free cash flow, debt refinancing, and potential for further AI partnerships after a recent deal with Palantir. Bullish sentiment seems to be building, with many anticipating a continued rise and some pointing to the long-term potential of LUMN.

Microsoft Corp. engages in the development and support of software, services, devices, and solutions. It operates through the following segments: Productivity and Business Processes, Intelligent Cloud, and More Personal Computing. The Productivity and Business Processes segment is composed of products and services relating to productivity, communication, and information services such as Office Commercial, Office Consumer, LinkedIn, and Dynamics business solutions. The Intelligent Cloud segment consists of public, private, and hybrid server products and cloud services for businesses and developers, as well as enterprise and partner services. The More Personal Computing segment refers to products and services including Windows operating system, Windows cloud services, Surface, HoloLens, personal computer accessories, Xbox hardware, Xbox Cloud Gaming, Microsoft News, and Microsoft Edge. The company was founded by Paul Gardner Allen and William Henry Gates, III in 1975 and is headquartered in Redmond, WA.

Microsoft Corporation

Microsoft Corp

Microsoft's stock is trending amid discussions about its earnings report and increased spending on AI, sparking mixed reactions from the community. Some investors express concerns over the heavy capital expenditures despite strong cloud growth, while others view the dip as a buying opportunity, citing the company's long-term potential and strategic positioning in the AI sector. Community members are actively debating the implications of the earnings results and the path forward for MSFT.

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Denver, CO.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantir is trending as the stock hits a new all-time high, sparking debates about its valuation and upcoming earnings. Community discussions revolve around whether the company can justify its current market cap, with some bulls pointing to recent partnerships and AI potential, while bears anticipate a potential earnings disappointment and pullback. The stock's high P/E ratio is a central point of contention among investors.

Roku, Inc. engages in the provision of a streaming platform for television. It operates through the Platform and Devices segments. The Platform segment includes digital advertising and related services including the demand-side platform and content distribution services such as subscription and transaction revenue shares, media and entertainment promotional spending, the sale of premium subscriptions, and the sale of branded channel buttons on remote controls. The Devices segment is involved in the sale of streaming players, audio products, smart home products, and accessories that are sold through retailers and distributors, as well as directly to customers through the company’s website. The company was founded by Anthony J. Wood in October 2002 and is headquartered in San Jose, CA.

Roku Inc - Ordinary Shares - Class A

Roku Inc

Roku is trending as investors discuss the potential impact of recent news and partnerships, particularly the Amazon advertising deal, on future revenue. Community members are debating whether the stock can finally break through the \$100 resistance level, while analysts are weighing in with price target upgrades. Some traders express frustration over the stock's historical volatility and sensitivity to market fluctuations, but remain optimistic about its long-term prospects in the streaming landscape.

Ardelyx, Inc. is a biopharmaceutical company, which engages in the business of developing and commercializing biopharmaceutical products. The firm is also involved in developing a unique and innovative platform that enables the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. The company was founded by Dominique Charmot, Peter G. Schultz, and Jean M. Frechet in October 2007 and is headquartered in Waltham, MA.

Ardelyx Inc

Ardelyx is trending following news of raising its FY2025 revenue forecast for its flagship drug, IBSRELA, leading to community excitement and discussion about potential future growth. Community members are actively discussing the potential for a significant price increase and the possibility of upgrades from analysts. Despite some profit-taking, the overall sentiment appears optimistic, with many emphasizing the company's strong fundamentals and long-term potential.

NLS Pharmaceutics Ltd. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of therapeutics for the treatment of neurobehavioral and neurocognitive disorders. Its product portfolio includes Quilience, a treatment for excessive daytime sleepiness and cataplexy associated with narcolepsy; and Nolazol, a treatment for attention deficit hyperactivity disorder. The company was founded by Ronald Hafner, Eric Konofal, and Alexander Zwyer on June 10, 2015 and is headquartered in Zurich, Switzerland.

NLS Pharmaceutics Ltd

NLSP is trending amid its merger with Kadimastem and an upcoming ticker change to NCEL, leading to much speculation and volatility. The community is actively discussing the reverse stock split, its impact on share value, and whether the merger will ultimately benefit shareholders. Concerns about potential dilution and the stock's unusual price action are also prevalent.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

NLS Pharmaceutics Ltd. and Kadimastem Ltd. Announce Completion of Merger

NLS Pharmaceutics Ltd. and Kadimastem Ltd. Announce Completion of Merger NLS Pharmaceutics Ltd. and Kadimastem Ltd. Announce Completion of Merger PR Newswire ZURICH and NESS ZIONA, Israel, Oct. 30...

NLS Pharmaceutics Expands CNS Pipeline With AEX-6xx Series Developed by Aexon Labs

NLS Pharmaceutics Expands CNS Pipeline With AEX-6xx Series Developed by Aexon Labs NLS Pharmaceutics Expands CNS Pipeline With AEX-6xx Series Developed by Aexon Labs PR Newswire ZURICH, Oct. 30, 2025...

NLS Pharmaceutics and Kadimastem Highlight Continued BIRD Foundation Support for ITOL-102 Diabetes Program Following Merger

NLS Pharmaceutics and Kadimastem Highlight Continued BIRD Foundation Support for ITOL-102 Diabetes Program Following Merger NLS Pharmaceutics and Kadimastem Highlight Continued BIRD Foundation...

NLS Pharmaceutics Ltd. Announces 1-for-10 Reverse Share Split and Name Change in Connection with Proposed Merger with Kadimastem

NLS Pharmaceutics Ltd. Announces 1-for-10 Reverse Share Split and Name Change in Connection with Proposed Merger with Kadimastem NLS Pharmaceutics Ltd. Announces 1-for-10 Reverse Share Split and Name...

NLS Pharmaceutics and Kadimastem Announce Completion of Material Conditions Precedent for Merger Transaction and Delisting Date of Kadimastem's Shares

NLS Pharmaceutics and Kadimastem Announce Completion of Material Conditions Precedent for Merger Transaction and Delisting Date of Kadimastem's Shares NLS Pharmaceutics and Kadimastem Announce...

NLS Pharmaceutics and Kadimastem Announce Strategic Collaboration between Kadimastem and TargetGene to Advance Next-Generation Gene-Edited Cell Therapies

NLS Pharmaceutics and Kadimastem Announce Strategic Collaboration between Kadimastem and TargetGene to Advance Next-Generation Gene-Edited Cell Therapies NLS Pharmaceutics and Kadimastem Announce...

NLS and Kadimastem Announce Receipt of Nasdaq Approval; Merger Expected to Close on October 30, 2025

NLS and Kadimastem Announce Receipt of Nasdaq Approval; Merger Expected to Close on October 30, 2025 NLS and Kadimastem Announce Receipt of Nasdaq Approval; Merger Expected to Close on October 30...

Kadimastem and iTolerance Successfully Complete Pre-IND Meeting with the FDA for its Type 1 Diabetes Treatment

Kadimastem and iTolerance Successfully Complete Pre-IND Meeting with the FDA for its Type 1 Diabetes Treatment Kadimastem and iTolerance Successfully Complete Pre-IND Meeting with the FDA for its...

NLS Pharmaceutics and Kadimastem Unveil Multi-Target Approach to Diabetes, Expanding Beyond GLP-1 Therapies

NLS Pharmaceutics and Kadimastem Unveil Multi-Target Approach to Diabetes, Expanding Beyond GLP-1 Therapies NLS Pharmaceutics and Kadimastem Unveil Multi-Target Approach to Diabetes, Expanding Beyond...

Kadimastem Shareholders Approved the Merger with NLS Pharmaceutics

Kadimastem Shareholders Approved the Merger with NLS Pharmaceutics Kadimastem Shareholders Approved the Merger with NLS Pharmaceutics PR Newswire ZURICH and NESS ZIONA, Israel, Jan. 31, 2025 ZURICH...

Will Palantir ($PLTR) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

) beat quarterly earnings? 
 
*Powered by Polymarket

NLSP
NLS Pharmaceutics Ltd

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest NLSP News

NLSPNLS Pharmaceutics Ltd